About Technomark LS
Technomark LS is a company founded in 1987. It operates as a Revenue Share and HealthTech. Technomark LS offers products and services including Clinical Development Solutions and Venture Capital Investment.
- SectorsHealthcare
- Website technomarkls.com
Products & Services of Technomark LS
Technomark LS offers a comprehensive portfolio of products and services, including Clinical Development Solutions and Venture Capital Investment.
Turn-key solutions for clinical development programs are provided.
Investment in life science companies is actively managed.
Similar companies to Technomark LS
10 companies that operate in the same segment as Technomark LS (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Technomark LS
Technomark LS was founded in 1987.
Technomark LS is recognized as an investment group specializing in life sciences, with a focus on therapeutics, med-tech, and diagnostics. Strategic planning and venture capital are provided to support portfolio companies. Turn-key solutions for clinical development programs are offered primarily in the US and Europe. Investments are made from seed to Series C stages, covering Phase I-IV clinical trials. A co-development investment model is followed, with returns through equity, royalties, and milestone payments. A global presence is maintained to facilitate innovative strategies for product development and corporate growth.
Technomark LS offers Clinical Development Solutions and Venture Capital Investment.